Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard Post History

by RoseHeaven


V.TLT

CR among Responders at 450 Days

Out of 46 evaluable patients at 450 days: - 14 patients never responded at...

January 15, 2024

V.TLT

RE:RE:RE:RE:pre-BTD and BTD

Hi DDawg: Thanks for all your inputs which are always amazing. One thing I do...

November 6, 2023

V.TLT

RE:RE:the protocol change notice from Health Canada

I have few questions about post 450 days CR data collection: - Can TLT...

October 29, 2023

V.TLT

RE:RE:RE:New Press Release - Theralase(R) Announces Brokered LIFE Financing

Stop crying baby! Let's get the fund they need to reach to the finished...

October 23, 2023

V.TLT

CTA-A NOL approval letter from Health Canada

Is this "CTA-A NOL approval letter" from Health Canada indicated in...

October 23, 2023

V.TLT

RE:RE:RE:RE:RE:TLT Successfully Completes Non-GLP Toxicity Study for GBM

Rutherrin® to be IV administered for numerous other cancers; including...

September 27, 2023

V.TLT

RE:RE:RE:TLT Successfully Completes Non-GLP Toxicity Study for GBM

The GLP toxicology program that Theralase® is completing will lay the...

September 27, 2023

V.TLT

RE:RE:RE:TLT Successfully Completes Non-GLP Toxicity Study for GBM

Based on the successful completion of the GLP toxicology program, Theralase...

September 27, 2023

V.TLT

RE:RE:TLT Successfully Completes Non-GLP Toxicity Study for GBM

Very exciting days ahead, this little gem is moving slowly but surely to make...

September 27, 2023

V.TLT

TLT Successfully Completes Non-GLP Toxicity Study for GBM

https://stockhouse.com/news/press-releases/2023/09/27/theralase-r...

September 27, 2023

V.TLT

GREAT NEWS-TLT Successfully Completes Non-GLP Toxicity Study

https://stockhouse.com/news/press-releases/2023/09/27/theralase-r...

September 27, 2023

V.TLT

450 days CR can increase as high as 47%

Based on the data trends, % CR can increase as high as 47% once all 58...

June 11, 2023

V.TLT

# of NR Patients in Swimmer Plots (May 10th & May 30th)

May 10th Swimmer's plot had 25 NR patients at 450D whereas today's...

May 31, 2023

V.TLT

RE:RE:RE:RE:RE:Becoming a commercial-stage pharmaceutical company

I already put him in ignore, I should have done it earlier. 

May 25, 2023

V.TLT

RE:RE:RE:Listening to a genius...(TLT best move).

Getting tired with his non-stop posting.

May 25, 2023

V.TLT

RE:RE:Listening to a genius...(TLT best move).

Who is this guy "Alamir1111" relentlessly jamming the entire...

May 25, 2023

V.TLT

CR Beyond 450 Days - A Potential differentiator for Rudivar

Just thinking what will happen to the patients who maintained CR status all...

May 2, 2023

V.TLT

RE:The new chart & the 450 days duration % numbers.

Agreed 100% with you. The new data format is the right way to go. The old...

April 29, 2023

V.TLT

Puzzles in Evaluable Patients

Evaluable Patients in previous News relase and ASCO Poster Patient had HG...

April 27, 2023

V.TLT

RE:RE:Another way to look at Efficacy

Thanks SF!   I believe FDA will be looking data from different...

February 22, 2023

1 2 3 4 Next

Featured Company